CN1283492A - A kind of Tibetan medicine for treating liver diseases and its preparation method - Google Patents
A kind of Tibetan medicine for treating liver diseases and its preparation method Download PDFInfo
- Publication number
- CN1283492A CN1283492A CN00121536A CN00121536A CN1283492A CN 1283492 A CN1283492 A CN 1283492A CN 00121536 A CN00121536 A CN 00121536A CN 00121536 A CN00121536 A CN 00121536A CN 1283492 A CN1283492 A CN 1283492A
- Authority
- CN
- China
- Prior art keywords
- tibetan medicine
- flos
- fructus
- medicine
- liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
本发明涉及一种治疗肝病的藏药及制备方法,具体的说是涉及一种由纯中藏药材制备而成的对慢性乙型肝炎、病毒性肝炎、肝硬化、肝腹水等有显著疗效的,又名为东格尔三十一味松石九的一种治疗肝病的藏药及制备方法。The present invention relates to a Tibetan medicine for treating liver diseases and a preparation method thereof, in particular to a kind of medicine which is prepared from pure Chinese and Tibetan medicinal materials and has significant curative effects on chronic hepatitis B, viral hepatitis, liver cirrhosis, liver ascites, etc. , also known as Dongger Sanyiwei Songshijiu, a Tibetan medicine for treating liver diseases and its preparation method.
目前,病毒性肝炎是一种严重危害人民生命健康的传染病,流行范围广,发病高,是其它传染病所不能比拟的,中国是乙肝病毒的高发区,据统计每年新增的乙型肝炎就有100万,在5型病毒性肝炎中乙型肝炎、丙型肝炎最易转为慢性,现已证实病毒性肝炎与肝硬化,原发性肝癌密切相关。虽然,藏医对治疗肝胆疾病有独到之处,传统配方较多,但由于饮食习惯等因素的不断变化,这些传统的配方有待于进一步的完善和强化。At present, viral hepatitis is an infectious disease that seriously endangers people's life and health. It has a wide range of prevalence and high incidence, which is unmatched by other infectious diseases. China is a high-incidence area of hepatitis B virus. There are 1 million of them. Among the 5 types of viral hepatitis, hepatitis B and C are most likely to become chronic. It has been confirmed that viral hepatitis is closely related to liver cirrhosis and primary liver cancer. Although Tibetan medicine has unique features in the treatment of liver and gallbladder diseases, and there are many traditional formulas, these traditional formulas need to be further improved and strengthened due to the constant changes in eating habits and other factors.
本发明的目的在于提供一种对慢性乙型肝炎,肝硬化等病毒性肝炎治愈率高,疗效快的一种治疗肝病的藏药及制备方法。The object of the present invention is to provide a kind of Tibetan medicine for treating liver disease with high cure rate and quick curative effect on chronic hepatitis B, viral hepatitis such as liver cirrhosis and its preparation method.
本发明的解决方案基于中医藏药理论,以《藏医临床札记》中的二十五味松石丸为基础,参照“珍宝达日丸”、“十三味红花丸”、“十六味松石丸”、“甘露月晶丸”、“七味红花殊胜丸”之处方,经二十多年的临床实践,反复加减与炮制,从祖国藏药宝库中,筛选出具有保肝利胆作用的松石、珊瑚、人工牛黄、五脉绿绒蒿、獐牙菜、藏红花;具有保肝解毒作用的珍珠、岩精膏、石花、骨碎补;具有解毒、养生功能,与其它药物混合后能提高药效并延长药物保质期限的佐太;具有清热、止血、健脾作用,作用于肝郁气滞、血瘀、脾脏不适的麻黄;具有解毒功能,用于食物中毒等各种毒症的骨碎补等31种药物原料混合研制成对肝郁气滞,肝中毒,病毒性肝炎,乙型肝炎,肝硬化,肝腹水疗效极佳的一种治疗肝病的藏药及制备方法。The solution of the present invention is based on the theory of traditional Chinese medicine and Tibetan medicine, based on the twenty-five-flavored Songshi pills in "Tibetan Medicine Clinical Notes", referring to "Zhenbao Dari Pills", "Thirteen Flavored Red Flower Pills", "Sixteen Flavored Songshi Pills" The prescriptions of "Stone Pill", "Nanlu Yuejing Pill" and "Qiwei Honghua Zhusheng Pill" have been selected from the treasury of Tibetan medicine in the motherland after more than 20 years of clinical practice, repeated addition, subtraction and processing. turquoise, coral, artificial bezoar, meconopsis five veins, watercress, and saffron; pearls, rock essence paste, stone flower, and rhizoma drynaria with liver protection and detoxification effects; detoxification and health-preserving functions. Zuotai, which can improve the efficacy and prolong the shelf life of medicines; has the functions of clearing away heat, stopping bleeding, and invigorating the spleen, and acts on ephedra, which acts on liver depression, stagnation of qi, blood stasis, and spleen discomfort; has detoxification functions, and is used for various toxicities such as food poisoning Drynaria rhizome and other 31 kinds of medicinal raw materials are mixed and developed into a Tibetan medicine for treating liver diseases with excellent curative effect on liver depression and qi stagnation, liver poisoning, viral hepatitis, hepatitis B, liver cirrhosis and liver ascites and its preparation method.
本发明的目的是这样实现的,它由松石、珍珠、珊瑚、银朱、余甘子、岩精膏、白檀香、紫檀香、波棱瓜子、广木香、肉豆蔻、丁香、獐牙菜、天竺黄、草红花、西红花、木棉花、石花、骨碎补、麻黄、佐太、草豆蔻、诃子、肉桂、赛北紫堇、人工牛黄、五脉绿绒蒿、唐古特乌头、毛诃子、麝香、藏木香配伍组成,经粉碎,过筛,配研、混匀,泛丸、干燥、包衣、打光、检验、包装等藏医加工炮制方法制备而成,其特征在于:它是由下述组分(重量份)制成的藏药:The purpose of the present invention is achieved in that it consists of turquoise, pearl, coral, silver vermilion, emblica, rock essence paste, white sandalwood, red sandalwood, waved melon seeds, broadwood, nutmeg, clove, watercress, Geranium yellow, grass safflower, saffron, kapok, stone flower, drynaria, ephedra, zotai, cardamom, myrobalan, cinnamon, safflower, artificial bezoar, meconopsis five veins, tangutou It is composed of the compatibility of head, chebula, musk, and Tibetan woody incense, and is prepared by Tibetan medicine processing methods such as crushing, sieving, blending, mixing, pan-pilling, drying, coating, polishing, inspection, and packaging. It is characterized in that it is a Tibetan medicine made from the following components (parts by weight):
松 石 20 珍 珠 5Pine Stone 20 Pearl 5
珊 瑚 5 银 朱 5Coral 5 Silver Vermilion 5
余甘子 5 岩精膏 5Phyllanthus emblica 5 rock extract 5
白檀香 5 紫檀香 5White Sandalwood 5 Rosewood 5
波棱瓜子 5 广木香 5Poleng melon seeds 5 Guangmuxiang 5
肉豆蔻 5 丁 香 5Nutmeg 5 cloves 5
獐牙菜 10 天竺黄 5Swertia 10 Tianzhuhuang 5
草红花 10 西红花 0.5Grass safflower 10 saffron 0.5
木棉花 5 石 花 5Kapok 5 Stone Flower 5
骨碎补 5 麻 黄 2.5Drynaria 5 5 Ephedra 2.5
佐 太 2.5 草豆蔻 5Zuotai 2.5 Grass cardamom 5
诃 子 10 肉 桂 15Myrobalan 10 Cinnamon 15
赛北紫堇 5 人工牛黄 5Saibei Viola 5 Artificial Bezoar 5
五脉绿绒蒿 10 唐古特乌头 15Meconopsis five veins 10 Aconitum tangut 15
毛诃子 5 麝 香 0.04Myrobalan 5 5 Musk 0.04
藏木香 10。Tibetan woody fragrance 10.
其特征还在于:所述的诃子和毛诃子均为去了核的诃子和毛诃子。It is also characterized in that: the described Myrobalan and Myrobalan are the cored Myrobalan and Myrobalan.
将上述各组分制成本发明藏药的制备方法是:The preparation method that above-mentioned each component is made Tibetan medicine of the present invention is:
①将名贵细药材佐太、牛黄、西红花、麝香分别研制成细粉,备用,① Grind the famous and precious fine medicinal materials Zuotai, bezoar, saffron and musk into fine powder respectively, and set aside for later use.
②将除上述名贵细药物之外的其余药材粉碎成细粉,过筛,②Crush the rest of the medicinal materials except the above-mentioned rare fine medicines into fine powder, sieve,
③加入佐太、牛黄、西红花、麝香细粉配研,混匀,③ Add Zotai, bezoar, saffron, and musk fine powder to grind, mix well,
④加岩精膏,加水泛丸,④ Add rock extract, add water pan pill,
⑤干燥,至含水量≤9.0%,⑤ Dry until the moisture content is ≤9.0%,
⑥包衣,打光,质量检查,成品包装,库存,即得本发明一种治疗肝病的藏药。6. coating, lighting, quality inspection, finished product packaging, stockpiling, a kind of Tibetan medicine for treating liver disease of the present invention is obtained.
本发明与现有技术相比,它质量稳定,服用安全、方便,疗效快,治愈率高,复发率低,服用后具有清热解毒、舒肝利胆、化瘀的功能,是一种对肝郁气滞、血瘀、肝中毒、肝痛、肝渗水,以及各种急慢性肝炎和胆囊炎,特别是对慢性乙型肝炎、肝硬化等病毒性肝炎有显著疗效的药物。Compared with the prior art, the present invention has stable quality, safe and convenient administration, fast curative effect, high cure rate and low recurrence rate, and has the functions of clearing away heat and detoxification, soothing liver and promoting gallbladder, and removing blood stasis after taking it. Qi stagnation, blood stasis, liver poisoning, liver pain, liver infiltration, and various acute and chronic hepatitis and cholecystitis, especially for chronic hepatitis B, cirrhosis and other viral hepatitis.
下面结合实施例进一步说明本发明Further illustrate the present invention below in conjunction with embodiment
实施例Example
①商购并称重下述重量(g)配比的原料① Commercially purchased and weighed raw materials with the following weight (g) ratio
松 石 20 珍 珠 5Pine Stone 20 Pearl 5
珊 瑚 5 银 朱 5Coral 5 Silver Vermilion 5
余甘子 5 岩精膏 5Phyllanthus emblica 5 rock extract 5
白檀香 5 紫檀香 5White Sandalwood 5 Rosewood 5
波棱瓜子 5 广木香 5Poleng melon seeds 5 Guangmuxiang 5
肉豆蔻 5 丁 香 5Nutmeg 5 cloves 5
獐牙菜 10 天竺黄 5Swertia 10 Tianzhuhuang 5
草红花 10 西红花 0.5Grass safflower 10 saffron 0.5
木棉花 5 石 花 5Kapok 5 Stone Flower 5
骨碎补 5 麻 黄 2.5Drynaria 5 5 Ephedra 2.5
佐 太 2.5 草豆蔻 5Zuotai 2.5 Grass cardamom 5
去核诃子 10 肉 桂 15Pit Myrobalan 10 Cinnamon 15
赛北紫堇 5 人工牛黄 5Saibei Viola 5 Artificial Bezoar 5
五脉绿绒蒿 10 唐古特乌头 15Meconopsis five veins 10 Aconitum tangut 15
去核毛诃子 5 麝 香 0.04Denuclear Myrobalan 5 Musk 0.04
藏木香 10Tibetan woody fragrance 10
②除名贵细药材(佐太、牛黄、西红花、麝香)与岩精膏另研细粉外,其余药物粉碎成细粉过100目筛,加入名贵细药材细粉配研,混匀,用岩精膏加适量水泛丸,干燥,含水量为5%,包衣,打光,质量检查,成品包装,库存即得黑色水丸、气香、味苦、涩的本发明一种治疗肝病的藏药,又名为东格尔三十一味松石丸。②Except for the fine powders of rare and precious herbs (Zuotai, Bezoar, Saffron, Musk) and Yanjing ointment, which are ground into fine powders and passed through a 100-mesh sieve, add the fine powders of precious herbs and grind, mix well, Add appropriate amount of water to pan pills with Yanjing ointment, dry, the water content is 5%, coating, polishing, quality inspection, finished product packaging, and stock to get black water pills, fragrant, bitter and astringent according to the present invention for treating liver diseases It is also known as Dongger Thirty-one Songshi Pills.
本发明的藏药经药效学表明(见附页),具有抗肝坏死及促进肝细胞修复作用,其免疫调节作用对消除病毒,稳定机体防御能力具有积极意义,对肝硬化动物的各项指标均有不同程度的改善作用;毒理学研究结果表明(见附页),较长疗程,较大剂量的服用该制剂对动物的血液学、血液生化学及重要组织器官无明显毒性损害,表明该制剂毒性低,口服安全。The Tibetan medicine of the present invention shows through pharmacodynamics (see attached page), has anti-hepatic necrosis and promotes hepatic cell repair effect, and its immunoregulatory effect has positive significance to eliminating virus, stabilizing body defense ability, and to each liver cirrhosis animal. Indexes all have different degrees of improvement; Toxicology research results show (see attached page), longer course of treatment, larger doses of taking the preparation have no obvious toxic damage to animal hematology, blood biochemistry and important tissues and organs, showing that The preparation has low toxicity and is safe to take orally.
经多年的临床观察结果表明,本发明的藏药对慢性乙型肝炎、肝硬化具有显著疗效。观察期间,未发现本发明藏药有明显的不良反应,服用安全,方便,对多种实验性肝损伤有明显的保护作用、抗纤维化作用明显,具有免疫增强作用和促进肝细胞再生作用,Years of clinical observation results show that the Tibetan medicine of the present invention has significant curative effects on chronic hepatitis B and liver cirrhosis. During the observation period, no obvious adverse reactions were found in the Tibetan medicine of the present invention. It is safe and convenient to take, has obvious protective effects on various experimental liver injuries, obvious anti-fibrosis effects, has immune enhancement effects and promotes liver cell regeneration,
现将临床实践中收集、整理慢性乙型肝炎56例,失代偿性肝硬化10例。对慢性乙型肝炎显效率32.1%,有效率为60.7%,总有效率92.8%,疗效明显优于对照药物(即一般保肝药物);对肝硬化的显效率为60%,有效率20%,总有效率为30%,临床实践观察期间,未发现本发明藏药有明显的不良反应,现将收集的病例分类整理如下:56 cases of chronic hepatitis B and 10 cases of decompensated liver cirrhosis are collected and sorted out in clinical practice. The effective rate for chronic hepatitis B is 32.1%, the effective rate is 60.7%, and the total effective rate is 92.8%. %, the effective rate is 20%, and the total effective rate is 30%. During the clinical practice observation period, no obvious adverse reactions are found in the Tibetan medicine of the present invention. The collected cases are classified as follows:
(一)本发明的藏药治疗乙型肝炎临床总结(1) Tibetan medicine of the present invention treats hepatitis B clinical summary
(1)一般资料(1) General information
慢性乙型肝炎诊断,依据1990年(上海)全国病毒性肝炎学术会修订的诊断标准,根据病程、症状、体征、实验室检查及乙型肝炎血清标记物检测作出诊断。56例中男34例,占60.7%,女22例,占39.2%,年龄最大59岁,最小16岁,随机与同期住院的慢性乙型肝炎20例(以一般保肝药物治疗)作为对照,男13例,女7例,年龄18-55岁。The diagnosis of chronic hepatitis B is based on the diagnostic criteria revised by the National Viral Hepatitis Academic Association in 1990 (Shanghai), and the diagnosis is made based on the course of disease, symptoms, signs, laboratory tests and serum markers of hepatitis B. Among the 56 cases, 34 were males, accounting for 60.7%, and 22 were females, accounting for 39.2%. The oldest was 59 years old and the youngest was 16 years old. Twenty cases of chronic hepatitis B were randomized and hospitalized at the same time (treated with general liver-protecting drugs). ) as a control, 13 males and 7 females, aged 18-55 years.
(2)治疗与疗效(2) Treatment and curative effect
治疗:一次1丸,每日二次,每丸重19,一个月为一疗程。Treatment: 1 pill each time, twice a day, each pill weighs 19, one month is a course of treatment.
疗效:Efficacy:
①疗效标准① Curative effect standard
显效:食欲正常,腹胀、恶心、腹泻消失,乏力消除,肝肿大缩小,质地中度以上硬者变软至适中,肝功能正常;Markedly effective: normal appetite, disappearance of abdominal distension, nausea, and diarrhea, elimination of fatigue, reduction of hepatomegaly, softening to moderate in those with moderate or higher texture, and normal liver function;
有效:上述症状消失,肝质地无变化,肝功能较前有进步;Effective: the above symptoms disappeared, the texture of the liver remained unchanged, and the liver function improved compared to before;
无效:和治疗前比较,各方面均无明显好转。Invalid: Compared with before treatment, there is no obvious improvement in all aspects.
②疗效② curative effect
治疗组therapy group
显效率32.1%(18/56); 有效率60.7%(34/56);The effective rate is 32.1% (18/56); the effective rate is 60.7% (34/56);
无效率7.1%(4/56); 总有效率92.8%(52/56)Ineffective rate 7.1% (4/56); total effective rate 92.8% (52/56)
对照组总有效率为35%(7/20),即:治疗组明显高于对照组。The total effective rate of the control group was 35% (7/20), that is, the treatment group was significantly higher than the control group.
(二)本发明的药物治疗肝硬化临床总结(2) clinical summary of drug treatment of liver cirrhosis of the present invention
肝硬化是一种常见的,又很顽固的危害性极大而无特效疗法的慢性疾病,现有的社会上尚无肯定的根治办法。然而,服用本发明的藏药治疗10例,近期效果满意。Liver cirrhosis is a common and stubborn chronic disease with great harm and no specific treatment, and there is no sure cure in the existing society. Yet take Tibetan medicine treatment of the present invention 10 cases, short-term effect is satisfactory.
(1)临床资料(1) Clinical data
本组共10例,其中男6例,女4例,最大者64例,最小者19岁。There were 10 cases in this group, including 6 males and 4 females, the oldest was 64 cases, and the youngest was 19 years old.
(2)临床表现:(2) Clinical manifestations:
主要症状为肝区痛,乏力,腹胀,发热,黄疸,脾大,肝大,腹水等。但肝硬化发展过程中,由于不同时期与病理解剖的不同变化或伴发其它疾病,可有各种少见的临床表现类型,常致误诊或漏诊。本组中有的表现为急腹症(胆囊炎、胆石症),有的表现为阻塞性黄疸,有的肝肿大明显表面不平而疑为肝癌,有的全身浮肿,尿样异常,表现为肾病等,本组10例根据症状、体征、肝功能、超声波等项检查,并结合临床分析作出诊断。The main symptoms are liver pain, fatigue, abdominal distension, fever, jaundice, splenomegaly, hepatomegaly, ascites, etc. However, during the development of liver cirrhosis, due to different changes in different periods and pathological anatomy or accompanying other diseases, there may be various rare clinical manifestations, which often lead to misdiagnosis or missed diagnosis. Some in this group showed acute abdomen (cholecystitis, cholelithiasis), some showed obstructive jaundice, some hepatomegaly was obviously uneven and suspected to be liver cancer, and some had systemic edema and abnormal urine samples, showing Kidney disease, etc., 10 cases in this group were diagnosed based on symptoms, signs, liver function, ultrasound and other items, combined with clinical analysis.
(3)治疗:(3) Treatment:
口服本发明药物每日二次,早晚各一次,饭后服用,一次一丸,每丸剂量为1克。Oral medicine of the present invention is taken twice a day, sooner or later each time, and is taken after meal, one pill, and the dosage of every pill is 1 gram.
(4)疗效标准(4) Curative effect standard
显效:肝脾大小如常,肝损消退,自觉症状消失。Significantly effective: the size of the liver and spleen is normal, the liver damage subsides, and the subjective symptoms disappear.
有效:肝脾回缩,自觉症状减轻。Effective: the liver and spleen are retracted, and the subjective symptoms are relieved.
无效:经过1-2的疗程的治疗,肝损及自觉症状均未减轻。Ineffective: After 1-2 courses of treatment, the liver damage and subjective symptoms were not relieved.
(5)疗效(5) curative effect
显效6例,占60%,有效2例,占20%,无效2例,占20%,总有效率80%6 cases were markedly effective, accounting for 60%, 2 cases were effective, accounting for 20%, 2 cases were ineffective, accounting for 20%, the total effective rate was 80%
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB001215361A CN1161132C (en) | 2000-08-10 | 2000-08-10 | Tibetan medicine for treating liver diseases and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB001215361A CN1161132C (en) | 2000-08-10 | 2000-08-10 | Tibetan medicine for treating liver diseases and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1283492A true CN1283492A (en) | 2001-02-14 |
CN1161132C CN1161132C (en) | 2004-08-11 |
Family
ID=4588858
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB001215361A Expired - Fee Related CN1161132C (en) | 2000-08-10 | 2000-08-10 | Tibetan medicine for treating liver diseases and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1161132C (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1329060C (en) * | 2005-05-25 | 2007-08-01 | 泽仁呷 | Combination of medication for treating hepatic disease, preparation method and application |
CN102058817A (en) * | 2010-11-01 | 2011-05-18 | 西藏金哈达药业有限公司 | Tibetan medicinal preparation for treating liver diseases |
CN102068653A (en) * | 2010-11-01 | 2011-05-25 | 西藏金哈达药业有限公司 | Medicament for preparing Tibetan medicament preparation for treating liver diseases |
CN107469002A (en) * | 2017-08-27 | 2017-12-15 | 内蒙古医科大学 | A kind of anaesthetic compound of anti-hepatic fibrosis |
CN112043758A (en) * | 2020-09-25 | 2020-12-08 | 兰科加 | A Chinese medicinal composition for treating liver cirrhosis and hepatic fibrosis |
-
2000
- 2000-08-10 CN CNB001215361A patent/CN1161132C/en not_active Expired - Fee Related
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1329060C (en) * | 2005-05-25 | 2007-08-01 | 泽仁呷 | Combination of medication for treating hepatic disease, preparation method and application |
CN102058817A (en) * | 2010-11-01 | 2011-05-18 | 西藏金哈达药业有限公司 | Tibetan medicinal preparation for treating liver diseases |
CN102068653A (en) * | 2010-11-01 | 2011-05-25 | 西藏金哈达药业有限公司 | Medicament for preparing Tibetan medicament preparation for treating liver diseases |
CN102058817B (en) * | 2010-11-01 | 2013-01-16 | 西藏金哈达药业有限公司 | Tibetan medicinal preparation for treating liver diseases |
CN107469002A (en) * | 2017-08-27 | 2017-12-15 | 内蒙古医科大学 | A kind of anaesthetic compound of anti-hepatic fibrosis |
CN112043758A (en) * | 2020-09-25 | 2020-12-08 | 兰科加 | A Chinese medicinal composition for treating liver cirrhosis and hepatic fibrosis |
Also Published As
Publication number | Publication date |
---|---|
CN1161132C (en) | 2004-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1515286A (en) | Chinese medicinal herb extractive | |
CN1695694A (en) | Chinese traditional medicine for treating breast disease and preparing technique | |
CN1283492A (en) | A kind of Tibetan medicine for treating liver diseases and its preparation method | |
CN1248721C (en) | Chinese medicine composition for treating consumptive disease and its quality control method | |
CN100335094C (en) | Notoginseng pain relieving plaster and its preparation method | |
CN102335416B (en) | Compound Chinese medicinal composition for treating hog cholera and preparation method thereof | |
CN1111046C (en) | Chinese medicine preparation for curing postpartum disease of woman | |
CN104546983A (en) | Primary and secondary plaster for treating rheumatism and preparation method thereof | |
CN1054541C (en) | Traditional Chinese medicine for treating mastosis | |
CN1228080C (en) | Blood activating Chinese medicinal composition in traumatology department and its preparing process | |
CN1557415A (en) | Medicine preparation for treating liver and gallbladder disease and its preparing process | |
CN1850248A (en) | Chinese medicine capsule for treating hyperplasia mammary glands and preparing method | |
CN1207054C (en) | Chinese medicine for treating pelvis, nephritis and kidney injury and preparing method thereof | |
CN1857378A (en) | Compound wild kiwi tablet and its preparing method | |
CN1165685A (en) | Bone soaking liquor | |
CN116327823B (en) | Pharmaceutical composition for rheumatoid arthritis and preparation method and application thereof | |
CN1366989A (en) | Medicine for curing tumor and its preparation method | |
CN1238011C (en) | Medicine for preventing and treating fowl pox | |
CN1061255C (en) | Anti-radioactivity fibration drug | |
CN1286480C (en) | Oral disintegrants of composite salvia miltiorrhiza and their preparation | |
CN1712055A (en) | Chinese medicinal preparation (litholytic capsule) for treating urinific calculus | |
CN1943732A (en) | A medicinal composition for treatment of psoriasis | |
CN1304043C (en) | Longhedan pills and their preparation | |
CN1739678A (en) | Medicine for treating pain caused by wind, cold and wetness evils and its prepn | |
CN1606987A (en) | Anti-allergic composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20040811 Termination date: 20150810 |
|
EXPY | Termination of patent right or utility model |